Enapotamab vedotin

N/A

Report date: 2024/02/05 13:57:37

Base Information

Drug NameEnapotamab vedotin
Drug Alias NameHuMax-AXLAxl-specific Antibody-drug Conjugateenapotamab vedotinAXL-107-MMAE
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTubulin inhibitors
TargetsAXL receptor tyrosine kinaseTubulin
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsEndometrial Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeagen IncGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesGenmab A/S
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsEndometrial Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A